Infectious Disease Doctors in East Brunswick, NJ Accepting Medicare

4 Infectious Disease doctors found. Showing 1 - 4

Dr. Marsha Kallich, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 579a Cranbury Rd, Suite 102, East Brunswick, NJ 08816 Phone: 732-613-0711    Fax: 732-613-5783

Dr. Ira Gurland, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 579a Cranbury Rd, Suite 102, East Brunswick, NJ 08816 Phone: 732-613-0711    Fax: 732-613-5783

Dr. Henry Redel, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 579a Cranbury Rd, Suite 102, East Brunswick, NJ 08816 Phone: 732-613-0711    Fax: 732-613-5783

Dr. Richard Snepar, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 579a Cranbury Rd, Suite 102, East Brunswick, NJ 08816 Phone: 732-613-0711    Fax: 732-613-5783

News Archive

New study reveals brain networks are involved in 'cross-modal' person recognition

Human social interactions are shaped by our ability to recognise people. Faces and voices are known to be some of the key features that enable us to identify individual people, and they are rich in information such as gender, age, and body size, that lead to a unique identity for a person.

Raydiance demonstrates ability to machine precise, micron-resolution features in gold, platinum

Raydiance, Inc., the world's leading developer of ultrafast laser technology, announced today that it has demonstrated the ability to machine precise, micron-resolution features in gold and platinum, two of the more difficult-to-process materials used in advanced medical devices. Raydiance engineers achieved the results using the company's Smart LightTM 50 femtosecond pulse laser integrated into a Rofin StarCut Tube workstation.

Head-to-head comparison of three breast cancer drugs reveals important differences

Every year, more than 250,000 women in the U.S. are diagnosed with breast cancer. When detected early, patients with the most common form-which tests positive for hormone receptors (HR+) and negative for the HER2 receptor-usually respond well to treatment.

Trends, R&D progress, and predicted revenues in RNAi therapies

When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Read more Medical News

› Verified 8 days ago